EGFR and cancer: Nowadays, EGFR inhibitors, including monoclonal antibodies and small-molecule TK inhibitors (TKIs), are approved as therapeutic options in solid tumors such as colorectal, head and neck, breast and lung cancers, since their overexpression or mutations are implicated in the pathogenesis of these cancer types [4].